Business Context and Reporting Period
This Form 8-K was filed by Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) on November 12, 2025. The filing reports two primary events: the effective change of the company's name from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., and the entry into a new material definitive agreement for a controlled equity offering.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential capital raise.
- Offering Capacity: Up to $200,000,000 in aggregate offering price.
- Commission: Up to 3.0% of gross proceeds payable to Cantor Fitzgerald & Co.
- Trading Symbol: LPTX (Nasdaq Capital Market).
Material Changes
The most significant material change reported is the execution of a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. This agreement allows the company to sell shares of its common stock from time to time through "at-the-market" offerings. Additionally, the company formally changed its legal name effective November 12, 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers. Key terms of the new agreement include:
- Discretionary Sales: The company has no obligation to sell any shares and may suspend offers at any time.
- Termination: Either party may terminate the agreement with ten business days' prior notice.
- Regulatory Basis: Shares will be issued pursuant to a shelf registration statement on Form S-3 filed in March 2024.
Investor Verification Checklist
- Verify the current trading status and ticker symbol (LPTX) on the Nasdaq Capital Market following the name change.
- Monitor future filings for actual sales volumes and proceeds generated under the new $200 million Sales Agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific price, time, or size limits the company may impose on Cantor.
- Confirm the impact of the name change on existing shareholder records and corporate governance documents.